Biogen Idec has announced that dexpramipexole, an experimental drug for the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, did not pass the Phase 3 clinical trial. The drug was not able to slow the loss of muscular function or lengthen the lifespan of patients with the condition. Therefore, Biogen has decided to not to experiment on this therapy anymore. ALS, a progressive neurodegenerative disorder, affects an estimated 30,000 people in the United States...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment